QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna™ TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab Agreements include a non-exclusive license for QIAGEN to the OncXerna Xerna™ TME panel The agreements broaden QIAGEN’s NGS companion diagnostics capabilities in immuno- oncology clinical […]



